Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BillionToOne, Inc.BLLN · Entity 3992 | Chief Administrative Officer | November 07, 2025 | November 12, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BillionToOne, Inc.
Report date November 07, 2025 · Filed November 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.15 · Expires 2035-08-04 | Direct | 0 |
Reported balance
After 2025-11-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-11-07 · Other · Disposed 133,300 · Balance 0 F1: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A common stock immediately prior to the completion of the Issuer's initial public offering of Class A common stock. F2: The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period, with 25% of the options vesting on July 7, 2026. The remaining 75%. vest and become exercisable in equal monthly installments over the following three years, subject to the Reporting Person's continuous service with the Issuer through each such vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.15 · Expires 2035-08-04 | Direct | 133,300 |
Reported balance
After 2025-11-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-11-07 · Other · Acquired 133,300 · Balance 133,300 F1: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A common stock immediately prior to the completion of the Issuer's initial public offering of Class A common stock. F2: The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period, with 25% of the options vesting on July 7, 2026. The remaining 75%. vest and become exercisable in equal monthly installments over the following three years, subject to the Reporting Person's continuous service with the Issuer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A common stock immediately prior to the completion of the Issuer's initial public offering of Class A common stock.
F2: The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period, with 25% of the options vesting on July 7, 2026. The remaining 75%. vest and become exercisable in equal monthly installments over the following three years, subject to the Reporting Person's continuous service with the Issuer through each such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
DEXCOM INC
Report date March 08, 2017 · Filed March 11, 2017
Section 16 reporting ended · disclosed 2017-03-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 93,732 |
Reported balance
After 2017-03-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-03-08 · Grant · Acquired 23,134 · Balance 93,732 F1: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock. F2: Included in this number are 67,634 unvested restricted stock units, 23,134 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 32,000 of which were granted on June 30, 2016 and shall vest through March 8, 2019 and 12,500 of which were granted on March 8, 2015 and shall vest through March 8, 2018. |
| Common StockSEC Table I · non-derivative | Direct | 96,732 |
Reported balance
After 2017-03-09 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2017-03-09 · Exercise / conversion · Acquired 3,000 · Balance 96,732 |
| Common StockSEC Table I · non-derivative | Direct | 93,732 |
Reported balance
After 2017-03-09 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2017-03-09 · Sale · Disposed 3,000 · Balance 93,732 F3: On December 13, 2016, Mr. Lister adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Lister. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4: This transaction was executed in multiple trades at prices ranging from $77.19 to $78.02. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2: Included in this number are 67,634 unvested restricted stock units, 23,134 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 32,000 of which were granted on June 30, 2016 and shall vest through March 8, 2019 and 12,500 of which were granted on March 8, 2015 and shall vest through March 8, 2018. |
| Common StockSEC Table I · non-derivative | Direct | 87,571 |
Reported balance
After 2017-03-10 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2017-03-10 · Disposition to issuer · Disposed 6,161 · Balance 87,571 F5: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2: Included in this number are 67,634 unvested restricted stock units, 23,134 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 32,000 of which were granted on June 30, 2016 and shall vest through March 8, 2019 and 12,500 of which were granted on March 8, 2015 and shall vest through March 8, 2018. |
| Common StockSEC Table I · non-derivative | Direct | 84,034 |
Reported balance
After 2017-03-10 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2017-03-10 · Disposition to issuer · Disposed 3,537 · Balance 84,034 F5: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2: Included in this number are 67,634 unvested restricted stock units, 23,134 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 32,000 of which were granted on June 30, 2016 and shall vest through March 8, 2019 and 12,500 of which were granted on March 8, 2015 and shall vest through March 8, 2018. |
| Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.85 · Expires 2018-01-14 | Direct | 10,939 |
Reported balance
After 2017-03-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-03-09 · Exercise / conversion · Disposed 3,000 · Balance 10,939 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock.
F2: Included in this number are 67,634 unvested restricted stock units, 23,134 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 32,000 of which were granted on June 30, 2016 and shall vest through March 8, 2019 and 12,500 of which were granted on March 8, 2015 and shall vest through March 8, 2018.
F3: On December 13, 2016, Mr. Lister adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Lister. The shares set forth above were sold pursuant to the 10b5-1 Plan.
F4: This transaction was executed in multiple trades at prices ranging from $77.19 to $78.02. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
F5: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 07, 2025 Filed Nov 12, 2025 23:09 UTC | BillionToOne, Inc. BLLN · Entity 3992 | OtherStock Option (right to buy) · Derivative | 133,300 | Not disclosed Strike: $23.15 | Not disclosed |
DisclosureSEC source: 0001193125-25-278126 · ownership.xml · derivative · entry 2 LISTER JOHN · CIK 0001464741 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,300 Underlying: Class A Common Stock · 133,300 shares Expires 2035-08-04 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A common stock immediately prior to the completion of the Issuer's initial public offering of Class A common stock. F1 · price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A common stock immediately prior to the completion of the Issuer's initial public offering of Class A common stock. F2 · derivative.exercise_date: The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period, with 25% of the options vesting on July 7, 2026. The remaining 75%. vest and become exercisable in equal monthly installments over the following three years, subject to the Reporting Person's continuous service with the Issuer through each such vesting date. Read SEC document |
| November 07, 2025 Filed Nov 12, 2025 23:09 UTC | BillionToOne, Inc. BLLN · Entity 3992 | OtherStock Option (right to buy) · Derivative | 133,300 | Not disclosed Strike: $23.15 | Not disclosed |
DisclosureSEC source: 0001193125-25-278126 · ownership.xml · derivative · entry 1 LISTER JOHN · CIK 0001464741 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 133,300 shares Expires 2035-08-04 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A common stock immediately prior to the completion of the Issuer's initial public offering of Class A common stock. F1 · price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A common stock immediately prior to the completion of the Issuer's initial public offering of Class A common stock. F2 · derivative.exercise_date: The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period, with 25% of the options vesting on July 7, 2026. The remaining 75%. vest and become exercisable in equal monthly installments over the following three years, subject to the Reporting Person's continuous service with the Issuer through each such vesting date. Read SEC document |
| March 10, 2017 Filed Mar 11, 2017 01:49 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 3,537 | $77.55 | $274,296.47 |
DisclosureSEC source: 0001093557-17-000065 · edgardoc.xml · nonDerivative · entry 5 LISTER JOHN · CIK 0001464741 · General Manager, EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,034 F5 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 67,634 unvested restricted stock units, 23,134 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 32,000 of which were granted on June 30, 2016 and shall vest through March 8, 2019 and 12,500 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| March 10, 2017 Filed Mar 11, 2017 01:49 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 6,161 | $77.55 | $477,789.25 |
DisclosureSEC source: 0001093557-17-000065 · edgardoc.xml · nonDerivative · entry 4 LISTER JOHN · CIK 0001464741 · General Manager, EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,571 F5 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 67,634 unvested restricted stock units, 23,134 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 32,000 of which were granted on June 30, 2016 and shall vest through March 8, 2019 and 12,500 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| March 09, 2017 Filed Mar 11, 2017 01:49 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 3,000 | $77.67 Strike: $8.85 | $233,001.90 |
DisclosureSEC source: 0001093557-17-000065 · edgardoc.xml · derivative · entry 6 LISTER JOHN · CIK 0001464741 · General Manager, EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,939 Underlying: Common Stock · 3,000 shares Expires 2018-01-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2017 Filed Mar 11, 2017 01:49 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,000 | $77.67 | $233,001.90 |
DisclosureSEC source: 0001093557-17-000065 · edgardoc.xml · nonDerivative · entry 3 LISTER JOHN · CIK 0001464741 · General Manager, EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,732 F3 · shares: On December 13, 2016, Mr. Lister adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Lister. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $77.19 to $78.02. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 67,634 unvested restricted stock units, 23,134 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 32,000 of which were granted on June 30, 2016 and shall vest through March 8, 2019 and 12,500 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| March 09, 2017 Filed Mar 11, 2017 01:49 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionCommon Stock | 3,000 | $8.85 | $26,550.00 |
DisclosureSEC source: 0001093557-17-000065 · edgardoc.xml · nonDerivative · entry 2 LISTER JOHN · CIK 0001464741 · General Manager, EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2017 Filed Mar 11, 2017 01:49 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 23,134 | $0.00 | $23.13 |
DisclosureSEC source: 0001093557-17-000065 · edgardoc.xml · nonDerivative · entry 1 LISTER JOHN · CIK 0001464741 · General Manager, EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,732 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock. F2 · balance_after: Included in this number are 67,634 unvested restricted stock units, 23,134 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 32,000 of which were granted on June 30, 2016 and shall vest through March 8, 2019 and 12,500 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| February 09, 2017 Filed Feb 14, 2017 00:19 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 3,000 | $79.73 Strike: $8.85 | $239,204.10 |
DisclosureSEC source: 0001093557-17-000029 · edgardoc.xml · derivative · entry 3 LISTER JOHN · CIK 0001464741 · General Manager, EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,939 Underlying: Common Stock · 3,000 shares Expires 2018-01-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2017 Filed Feb 14, 2017 00:19 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,000 | $79.73 | $239,204.10 |
DisclosureSEC source: 0001093557-17-000029 · edgardoc.xml · nonDerivative · entry 2 LISTER JOHN · CIK 0001464741 · General Manager, EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,598 F1 · shares: On December 13, 2016, Mr. Lister adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Lister. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $79.41 to $80.32. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 61,584 unvested restricted stock units, 32,000 of which were granted on June 30, 2016 and shall vest through March 8, 2019, 18,750 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 10,834 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
| February 09, 2017 Filed Feb 14, 2017 00:19 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionCommon Stock | 3,000 | $8.85 | $26,550.00 |
DisclosureSEC source: 0001093557-17-000029 · edgardoc.xml · nonDerivative · entry 1 LISTER JOHN · CIK 0001464741 · General Manager, EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,598 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 13, 2017 Filed Jan 19, 2017 00:38 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 15,000 | $79.36 Strike: $8.85 | $1,190,400.00 |
DisclosureSEC source: 0001093557-17-000013 · edgardoc.xml · derivative · entry 3 LISTER JOHN · CIK 0001464741 · General Manager, EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,939 Underlying: Common Stock · 15,000 shares Expires 2018-01-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 13, 2017 Filed Jan 19, 2017 00:38 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 15,000 | $79.36 | $1,190,400.00 |
DisclosureSEC source: 0001093557-17-000013 · edgardoc.xml · nonDerivative · entry 2 LISTER JOHN · CIK 0001464741 · General Manager, EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,598 F1 · shares: On December 13, 2016, Mr. Lister adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Lister. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 61,584 unvested restricted stock units, 32,000 of which were granted on June 30, 2016 and shall vest through March 8, 2019, 18,750 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 10,834 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
| January 13, 2017 Filed Jan 19, 2017 00:38 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionCommon Stock | 15,000 | $8.85 | $132,750.00 |
DisclosureSEC source: 0001093557-17-000013 · edgardoc.xml · nonDerivative · entry 1 LISTER JOHN · CIK 0001464741 · General Manager, EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,598 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 09, 2017 Filed Jan 12, 2017 00:33 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 3,000 | $63.02 Strike: $8.85 | $189,045.90 |
DisclosureSEC source: 0001093557-17-000007 · edgardoc.xml · derivative · entry 3 LISTER JOHN · CIK 0001464741 · General Manager, EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,939 Underlying: Common Stock · 3,000 shares Expires 2018-01-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 09, 2017 Filed Jan 12, 2017 00:33 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,000 | $63.02 | $189,045.90 |
DisclosureSEC source: 0001093557-17-000007 · edgardoc.xml · nonDerivative · entry 2 LISTER JOHN · CIK 0001464741 · General Manager, EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,598 F1 · shares: On December 13, 2016, Mr. Lister adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Lister. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $62.50 to $63.67. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 61,584 unvested restricted stock units, 32,000 of which were granted on June 30, 2016 and shall vest through March 8, 2019, 18,750 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 10,834 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
| January 09, 2017 Filed Jan 12, 2017 00:33 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionCommon Stock | 3,000 | $8.85 | $26,550.00 |
DisclosureSEC source: 0001093557-17-000007 · edgardoc.xml · nonDerivative · entry 1 LISTER JOHN · CIK 0001464741 · General Manager, EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,598 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 23:31 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,417 | $62.50 | $213,562.50 |
DisclosureSEC source: 0001093557-16-000749 · edgardoc.xml · nonDerivative · entry 1 LISTER JOHN · CIK 0001464741 · General Manager, EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,598 F1 · shares: On November 12, 2015, Mr. Lister adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Lister. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 61,584 unvested restricted stock units, 32,000 of which were granted on June 30, 2016 and shall vest through March 8, 2019, 18,750 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 10,834 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
| October 10, 2016 Filed Oct 13, 2016 00:59 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,560 | $84.41 | $300,508.14 |
DisclosureSEC source: 0001093557-16-000723 · edgardoc.xml · nonDerivative · entry 1 LISTER JOHN · CIK 0001464741 · General Manager, EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,015 F1 · shares: On November 12, 2015, Mr. Lister adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Lister. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $83.52 to $85.07. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 61,584 unvested restricted stock units, 32,000 of which were granted on June 30, 2016 and shall vest through March 8, 2019, 18,750 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 10,834 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
| September 09, 2016 Filed Sep 14, 2016 00:33 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 3,525 | $93.72 | $330,372.52 |
DisclosureSEC source: 0001093557-16-000698 · edgardoc.xml · nonDerivative · entry 3 LISTER JOHN · CIK 0001464741 · General Manager, EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,575 F4 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F3 · balance_after: Included in this number are 61,584 unvested restricted stock units, 32,000 of which were grant on June 30, 2016 and shall vest through March 8, 2019, 18,750 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 10,834 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
| September 09, 2016 Filed Sep 14, 2016 00:33 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 6,114 | $93.72 | $573,020.59 |
DisclosureSEC source: 0001093557-16-000698 · edgardoc.xml · nonDerivative · entry 2 LISTER JOHN · CIK 0001464741 · General Manager, EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,100 F4 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F3 · balance_after: Included in this number are 61,584 unvested restricted stock units, 32,000 of which were grant on June 30, 2016 and shall vest through March 8, 2019, 18,750 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 10,834 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
| September 09, 2016 Filed Sep 14, 2016 00:33 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,560 | $93.65 | $333,391.51 |
DisclosureSEC source: 0001093557-16-000698 · edgardoc.xml · nonDerivative · entry 1 LISTER JOHN · CIK 0001464741 · General Manager, EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,214 F1 · shares: On November 12, 2015, Mr. Lister adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Lister. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $92.86 to $94.57. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 61,584 unvested restricted stock units, 32,000 of which were grant on June 30, 2016 and shall vest through March 8, 2019, 18,750 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 10,834 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
| September 09, 2016 Filed Sep 14, 2016 00:32 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 3,525 | $93.72 | $330,372.52 |
DisclosureSEC source: 0001093557-16-000694 · edgardoc.xml · nonDerivative · entry 3 LISTER JOHN · CIK 0001464741 · General Manager, EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,575 F4 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F3 · balance_after: Included in this number are 61,584 unvested restricted stock units, 32,000 of which were grant on June 30, 2016 and shall vest through March 8, 2019, 18,750 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 10,834 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
| September 09, 2016 Filed Sep 14, 2016 00:32 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 6,114 | $93.72 | $573,020.59 |
DisclosureSEC source: 0001093557-16-000694 · edgardoc.xml · nonDerivative · entry 2 LISTER JOHN · CIK 0001464741 · General Manager, EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,100 F4 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F3 · balance_after: Included in this number are 61,584 unvested restricted stock units, 32,000 of which were grant on June 30, 2016 and shall vest through March 8, 2019, 18,750 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 10,834 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
| September 09, 2016 Filed Sep 14, 2016 00:32 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,560 | $93.65 | $333,391.51 |
DisclosureSEC source: 0001093557-16-000694 · edgardoc.xml · nonDerivative · entry 1 LISTER JOHN · CIK 0001464741 · General Manager, EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,214 F1 · shares: On November 12, 2015, Mr. Lister adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Lister. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $92.86 to $94.57. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 61,584 unvested restricted stock units, 32,000 of which were grant on June 30, 2016 and shall vest through March 8, 2019, 18,750 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 10,834 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.